Low-Risk TAVR Studies: Divergent Long-Term Results

Different results from long-term follow-up of the PARTNER-3 and Evolut trials evaluating TAVR vs surgery in low-surgical-risk patients are leading to some interesting discussions.

Related Keywords

San Francisco ,California ,United States ,Corevalve Evolut ,Michael Reardon ,Edwards Lifesciences ,Coll Cardiol ,York Heart Association ,Medtronic ,Presbyterian Columbia University Irving Medical Center ,Houston Methodist Debakey Heart Vascular Center ,Transcatheter Cardiovascular Therapeutics ,New England Journal ,Medscape Cardiology ,Houston Methodist Debakey Heart ,Vascular Center ,New York Heart Association ,Difference Between ,Cardiovascular Therapeutics , ,Surgery ,Thromboembolism ,Stroke ,Erebrovascular Accident ,Va Cerebrovascular Accident ,Congenital Heart Disease ,Atrial Fibrillation ,F Atrial Fibrillation ,Transcatheter Aortic Valve Replacement Tavr ,Ranscatheter Aortic Valve Implantation Tavi ,Percutaneous Aortic Valve Replacement ,Aortic Valve ,Aortic Insufficiency ,Arrhythmia ,Hemodynamics ,Hemodynamic Monitoring ,Heart Failure ,Heart ,Card ,